Investor Relations

Investor Relations

Company News, Updates and Press Releases

Investors2025-09-18T13:31:54-04:00

Building better oncology tools

Company Overview

AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We take a holistic view of our role in oncology- to empower patients and their care team with critical answers and tools that support more informed decision making.

Our Technology

We are building an ecosystem of products that will change how cancer is treated and managed.

ACUT Chart by TradingView

Accustem Sciences, Inc (ACUT)

Accustem Sciences Inc started trading on the OTC under ACUT on March 2, 2022. For more investor information please contact us using our contact form or emailing us at [email protected]

Accustem Sciences, Inc (ACUT)

Accustem Sciences Inc started trading on the OTC under ACUT on March 2, 2022. For more investor information please contact us using our contact form or emailing us at [email protected]

Annual and Interim reports

Latest Corporate Presentation

Investor Video Presentations

Latest news

Information For Shareholders Regarding Accustem Shares

Holders of record of shares of Accustem Sciences Inc should refer to the below instructions regarding the process to receive their shares. Please contact Pacific Stock Transfer Company (“PSTC”) with any questions regarding the process.

If you wish to transfer your shares to a U.S. bank or broker, follow the steps below:

  1. Send a copy of your DRS Statement to your broker.
  2. Your broker will set up what is known as a “DRS Profile” to sweep the shares from PST’s database based on the information in the DRS Statement.  
  3. Provided the request matches the information on PSTC’s database, the shares will transfer from PSTC to your broker.
  4. Your broker will internally allocate the shares to your personal account at that broker.

If you wish to transfer your shares to a non-U.S. bank or broker, follow the steps below:

  1. Send a copy of your DRS statement to your local broker and advise them that they need to set up a “DRS Profile” (and no other type of trade) to “pull” the shares from PST in the United States. This is a technical process but given the international nature of securities markets, your broker’s settlement agent will understand the required process.
  2. The local broker then must interact with their operations team to properly instruct their U.S. clearing agent to set up a DRS Profile request on their behalf based on the information in the DRS Statement.
    Note: The local broker should refer to their U.S. clearing agent for any guidance if they are not clear on the appropriate format of the instruction, as this part of the process is an internal matter.
  3. The U.S. clearing agent will set up a DRS Profile to “pull” your shares from PST’s database based on the information in the DRS Statement.
  4. Provided the request matches the information on PST’s database, the shares will transfer from PST to the U.S. clearing agent.
  5. The U.S. clearing agent will internally allocate your shares to the account of your local broker.
  6. Your local broker will internally allocate the shares to your personal account at your broker.

  1. Send a copy of the DRS Statement to your US clearing agent and advise them that a DRS Profile (and no other type of trade) should be set up to pull the shares from PST in the United States.
  2. You must interact internally with their operations team to properly instruct their U.S. clearing agent to set up a DRS Profile request on their behalf based on the information in the DRS Statement. This will generally include the customer registration name, PSTC account number, and total number of shares. You will need to communicate internally to their U.S. clearing agent for any guidance if they are not clear on the appropriate format of the instruction, as this part of the process is an internal matter.
  3. The U.S. clearing agent will set up a DRS Profile on behalf of the UK broker to sweep the shares from PSTC’s database based on the information in the DRS Statement.
  4. Provided the request matches the information on PSTC’s database, the shares will transfer from PST to the U.S. clearing agent.
  5. The U.S. clearing agent will internally allocate the shares to the account of their customer, the UK broker
  6. You will then internally allocate the shares at their firm to the custody positions of their underlying customers upon receipt of the shares.

If you have not received your DRS Statement and you are a certified shareholder or a broker/nominee, please contact us on [email protected] further assistance. Alternatively, you can contact Pacific Stock Transfer Company directly at
[email protected]

Accustem shares will not show up in your account unless the broker has taken the appropriate action via the DTCC Clearing system.

If your shares are not showing in your account with your broker, please contact your broker directly.

You, together with your broker, should contact Pacific Stock Transfer Company with any questions on transferring your shares. You can contact PST by:

Calling: +1 (702) 361-3033 
Emailing:[email protected] or
Writing to: 6725 Via Austi Pkwy Suite 300, Las Vegas, NV
89119

The website for PSTC is: www.pacificstocktransfer.comw

Accustem Sciences, Inc
14-15 Conduit Street
London, W1S 2XJ

Useful Links

Stay Informed

Accustem Sciences, Inc © 2025

Keeren Shah

Chief Finance Officer

Keeren has held a variety of leadership roles in Finance over the last 20 years. In addition to serving as AccuStem’s Chief Financial Officer, she also serves as the Chief Financial Officer of OKYO Pharma Ltd, Tiziana Life Sciences, Ltd. and Rasna Therapeutics Inc., having previously served as the Group Financial Controller for all businesses from June 2016 to July 2020. Prior to joining this portfolio of companies, Keeren spent 10 years at Visa, Inc. as a senior leader on its Finance team where she was responsible for key financial controller activities, financial planning and analysis, core processes as well as leading and participating in key transformation programs including Visa Inc.’s initial public offering. Before joining Visa, Keeren also held a variety of finance positions at other leading companies including Arthur Andersen and BBC Worldwide. She holds a Bachelor of arts with honours in Economics and is a member of the Chartered Institute of Management Accountants.

Keeren Shah

Chief Finance Officer

Keeren has held a variety of leadership roles in Finance over the last 20 years. In addition to serving as AccuStem’s Chief Financial Officer, she also serves as the Chief Financial Officer of OKYO Pharma Ltd, Tiziana Life Sciences, Ltd. and Rasna Therapeutics Inc., having previously served as the Group Financial Controller for all businesses from June 2016 to July 2020. Prior to joining this portfolio of companies, Keeren spent 10 years at Visa, Inc. as a senior leader on its Finance team where she was responsible for key financial controller activities, financial planning and analysis, core processes as well as leading and participating in key transformation programs including Visa Inc.’s initial public offering. Before joining Visa, Keeren also held a variety of finance positions at other leading companies including Arthur Andersen and BBC Worldwide. She holds a Bachelor of arts with honours in Economics and is a member of the Chartered Institute of Management Accountants.

Joe Flanagan

Chief Business Officer

Joe has 25 years of sales excellence experience and is one of the most sought after talents in Oncology. He is a strategic expert, playing a leading role in the commercial development and successful launch of several product offerings from early-stage diagnostic start ups to large pharmaceutical companies. Prior to joining Accustem, Joe served as the VP of Sales for Precision Therapeutics as well as the VP of Market Development for Biodesix and Agendia. During his tenure, record revenues were realized as a result of his efforts to enhance the clinical agility and logistical focus of each company’s sales team. Most recently, he led strategic development efforts with Ambry Genetics’ Oncology franchise.

Wendy Blosser

Chief Executive Officer

Wendy brings 25 years of success launching, relaunching and building organizations in diagnostic, surgical and capital sales, with a focus in Oncology and Women’s Health. She has achieved record revenue growth at a variety of organizations from early-stage start ups to Fortune 500 companies. Most recently, Wendy has served as CCO at Agendia, Animated Dynamics and Biodesix. Prior to Biodesix, Wendy served as VP of Sales with Integrated Oncology (LabCorp subsidiary) where she lead the successful integration of Genzyme Genetics following its acquisiton for $925M. Before joining Integrated Oncology, she held several leadership roles with Cytyc Corporation prior to its $6.2B acquisition by Hologic.

Jeff Fensterer

Chief Operating Officer

Jeff has spent the last 20 years with start ups at various organizational stages, leading marketing and product strategy in his most recent roles at Agendia, Animated Dynamics and Biodesix. His scientific expertise and keen commercial perspective enable organizations to take clinical data and translate it into impactful product messaging and publication strategies. His exceptional track record in long-term strategic planning is enhanced by experience in a broad spectrum of roles including marketing, sales, R&D, market access, lab operations, clinical development, business development and IT. Jeff holds a MBA from Carnegie Mellon University.

Go to Top